Market Cap | 4.61M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -415.28k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -34.00% |
Sales | 87.28k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -43.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -85.00% |
Recommedations | - | Quick Ratio | 0.09 | Shares Outstanding | 127.45M | 52W Low Chg | 144.00% |
Insider Own | 9.52% | ROA | - | Shares Float | - | Beta | 1.80 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00049 |
Gross Margin | 185.89% | Profit Margin | - | Avg. Volume | 41,746,098 | Target Price | - |
Oper. Margin | -216.32% | Earnings Date | - | Volume | 24,986,943 | Change | -11.27% |
GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.